Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) announced that the European Medicines Agency's CHMP recommended approval of Opdivo (nivolumab) with Yervoy (ipilimumab) for adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) after prior chemotherapy. This decision stemmed from the Phase 2 CheckMate -142 trial. The European Commission will review this recommendation. This combination has previously received FDA approval in July 2018 and Japan in September 2020, highlighting its significance in addressing a critical treatment gap.
Bristol Myers Squibb (NYSE: BMY) announced FDA approval for Opdivo® (nivolumab) as an adjuvant treatment for completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual disease post-neoadjuvant chemoradiotherapy. The approval follows the CheckMate -577 trial, showing a median disease-free survival of 22.4 months for Opdivo versus 11.0 months for placebo, indicating a 31% reduction in recurrence risk. This approval represents a significant advancement in treatment options for aggressive cancer types.
Bristol Myers Squibb (NYSE: BMY) has elected Dr. Manuel Hidalgo Medina to its Board of Directors, effective June 1, 2021. Dr. Hidalgo, a prominent figure in oncology, is currently the chief of hematology and medical oncology at Weill Cornell Medicine. His extensive experience in anticancer drug development, particularly in gastrointestinal cancers, is expected to enhance the company's scientific leadership. The board's size will increase to 11 members with his election, aimed at advancing Bristol Myers Squibb's long-term strategy in innovative medicine.
Bristol Myers Squibb (NYSE: BMY) announced that in the Phase 3 CheckMate -9LA trial, the combination of Opdivo and Yervoy with two cycles of chemotherapy resulted in a significant survival benefit for patients with advanced non-small cell lung cancer (NSCLC). After two years, 38% of patients on the combination therapy were alive compared to 26% receiving chemotherapy alone. Median overall survival was 15.8 months for the combination versus 11.0 months for chemotherapy. Safety profiles were consistent with previous studies, and secondary endpoints showed improved progression-free survival and overall response rates.
Bristol Myers Squibb (NYSE: BMY) announced positive long-term survival data from the Phase 3 CheckMate -227 trial comparing the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) against chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). With a follow-up of 49.4 months, the four-year survival rates were 29% for the combination therapy versus 18% for chemotherapy in patients with PD-L1 expression ≥1%. The dual therapy demonstrated improved survival across various PD-L1 expression levels, affirming its potential as a first-line option against NSCLC.
Bristol Myers Squibb (NYSE: BMY) presented six-and-a-half-year results from the CheckMate -067 trial, showing significant survival benefits for patients with advanced melanoma treated with Opdivo (nivolumab) plus Yervoy (ipilimumab). The median overall survival was reported at 72.1 months for the combination therapy, the longest in a Phase 3 trial for this condition. Progression-free survival rates were 34% for the combination, compared to 29% and 7% for Opdivo and Yervoy alone, respectively. Safety profiles remained consistent with past studies, indicating sustained benefits of the treatment regimen.
Bristol Myers Squibb (BMY) and bluebird bio (BLUE) revealed new findings from the pivotal KarMMa study on Abecma (idecabtagene vicleucel), a CAR T cell therapy for multiple myeloma. Updated results show a consistent overall response rate of 73% and a complete response in 33% of patients after a median follow-up of 24.8 months. The safety profile indicates common adverse events include cytopenias (97%) and cytokine release syndrome (84%). Abecma remains the first BCMA-directed CAR T therapy approved by the FDA, with ongoing reviews in other regions.
Bristol Myers Squibb (NYSE: BMY) announced promising results from the Phase 2/3 RELATIVITY-047 trial, demonstrating that the combination of relatlimab and nivolumab significantly improved progression-free survival (PFS) in patients with untreated metastatic melanoma compared to Opdivo alone. The median PFS was 10.12 months for the combination versus 4.63 months for Opdivo (p=0.0055). This regimen is the first to show a statistical benefit over anti-PD-1 therapy in this patient group. The safety profile was consistent with previous studies, highlighting its potential as a new treatment option.
Bristol-Myers Squibb (BMY) has secured a global exclusive license for Agenus' bispecific antibody AGEN1777, targeting TIGIT. The deal entails a $200 million upfront payment and additional potential milestones totaling up to $1.36 billion, plus royalties on sales. AGEN1777, designed to enhance anti-tumor activities, is currently in late preclinical development, with an IND application expected in Q2 2021. Bristol-Myers Squibb aims to advance AGEN1777 for high-priority tumor indications like non-small cell lung cancer, highlighting its commitment to immuno-oncology.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 25, 2021. The session will feature David Elkins, CFO, and Samit Hirawat, Chief Medical Officer, answering questions about the company at 1 p.m. ET. Investors and the public can listen to the live webcast at investor.bms.com, and an archived version will be available later the same day.
Bristol Myers Squibb, a global biopharmaceutical company, focuses on developing innovative medicines for serious diseases.